The firm originally raised $55.5 million in the round in February 2018, and said investors added $30 million in December and another $20 million more recently.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
The firm said the purchase will allow it to better provide software tools to customers in the chemistry, pharmaceutical, and analytical laboratory markets.
Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.
